Biomay Ag | Date: 2017-03-08
The present invention relates to a fusion protein for use in the treatment and/or prevention of a hepatitis B virus infection comprising at least one hepatitis B PreS polypeptide or fragment thereof fused to at least one peptide consisting of an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.3-3 | Award Amount: 9.59M | Year: 2014
Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact. Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers. Allergen-specific immunotherapy is the only causal and effective treatment targeting the underlying immune mechanism in a more cost-effective way. Yet, long treatment duration and risk of anaphylactic side-effects have prevented this treatment from becoming the first choice. BM4SIT aims at providing an escape from its current niche position by making the treatment safer, more effective and patient friendlier, i.e. developing a therapy with negligible side-effects but improved efficacy, achieved by less injections. The concept of BM4SIT is based on two innovations: replacing current natural allergen extracts by mutated recombinant allergens having been designed to be hypo-allergenic but hyper-immunogenic, and adding an adjuvant to support rapid and effective induction of an anti-inflammatory immune response. The allergen derivative chosen to bring this concept from bench to bedside is BM4, a mutant of the culprit allergen of birch pollen allergy, Bet v 1. Pre-clinical data have demonstrated strongly reduced allergenicity, significantly increased immunogenicity and efficacy in a mouse model for birch pollen allergy. The selected adjuvant is vitamin D3, which has been shown to promote active suppression of inflammation, both in vitro and in a mouse model. The product-focused, IP-protected consortium of BM4SIT will bring BM4 and vitamin D3 to the start of Phase III clinical trials via the stages of GMP production, toxicity studies, and Phase I and II clinical trials. Addition of vitamin D3 will first be evaluated against placebo and a current product, followed by a safety and dose-range-finding study using BM4 and vitamin D3. BM4SIT will pave the way towards a better more attractive therapy that will improve the cost-benefit ratio compared to symptomatic drugs.
Biomay Ag | Date: 2015-12-17
The present invention relates to a hypoallergenic protein consisting of at least one hypoallergenic molecule derived from an allergen, which is fused or conjugated to at least one second non-allergenic protein or fragment thereof.
Biomay AG | Date: 2014-08-26
A polypeptide containing an amino acid sequence having at least 60% identity to the amino acid sequence SEQ ID No. 1 or containing at least one amino acid fragment of at least 6 consecutive amino acid residues of the amino acid sequence SEQ ID No. 1 or having immunological cross-reactivity to the amino acid sequence SEQ ID No. 1 or fragments thereof, wherein the amino acid sequence SEQ ID No. 1 codes for an allergen and the polypeptide comprises at least one T cell epitope recognized by a T cell receptor specific for a molecule having the amino acid sequence SEQ ID No. 1.
Biomay Ag | Date: 2014-03-14
The present invention relates to a method for detecting and/or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence and/or amount of antibodies binding to a) a peptide consisting of the amino acid sequence AIVCTRPNNNTRKSIRIGPGQVFYT (SEQ ID No. 1), or b) a homolog having at least 70% identity with a peptide of a), or c) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues in said sample.
Biomay Ag | Date: 2013-11-20
The present invention relates to a method for producing a hypoallergenic variant of an allergenic polypeptide having one or more loop regions comprising the step of modifying at least one loop region within the allergenic polypeptide by dividing said at least one loop region into at least two fragments, each of said fragments comprising at least 4 amino acid residues and rejoining said at least two fragments in a different order than in said allergenic polypeptide.
Biomay Ag | Date: 2015-09-30
The present invention relates to a hypoallergenic molecule derived from Phl p 5 and consisting of 15 to 40 amino acids, wherein said molecule comprises amino acids 26 to 58, 176 to 212, 217 to 246, 93 to 128, 98 to 128, 26 to 53, 252 to 283 or 132 to 162 of Phl p 5 or a variant of these fragments truncated by 1 to 5 amino acid residues.
Biomay Ag | Date: 2016-05-03
The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.
Biomay Ag | Date: 2015-05-01
The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the N- and C-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.
Biomay Ag | Date: 2014-09-17
The present invention relates to a methodfor diagnosing a human immunodeficiency virus (HIV) infection in a subject comprising the step of determining the presence of antibodies binding toa) a peptide consisting of the amino acid sequence AIVCTRP-NNNTRKSIRIGPGQVFYT (SEQ ID No. 1), orb) a homolog having at least 70% identity with a peptide of a), orc) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues,in a sample of the subject.